Deal-Hungry Actavis Inks $675M Deal To Boost Disease Biz
Actavis PLC said Monday that it will beef up its infectious disease portfolio by absorbing Durata Therapeutics Inc. in a deal worth $675 million as rumors swirl that the deal-hungry drugmaker...To view the full article, register now.
Already a subscriber? Click here to view full article